Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
13 hedge funds and large institutions have $576K invested in Northwest Biotherapeutics, Inc. Common stock in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 0 closing their positions.
30% more funds holding
Funds holding: 10 → 13 (+3)
27% more capital invested
Capital invested by funds: $453K → $576K (+$123K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$262K |
| 2 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$44.5K |
| 3 |
AIP
Almanack Investment Partners
Wayne,
Pennsylvania
|
+$13.5K |
| 4 |
ECM
Estabrook Capital Management
New York
|
+$7K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AA
1
Ancora Advisors
Cleveland,
Ohio
| $263K | +$262K | +375,150 | +37,515% |
|
|
MSAM
2
Moloney Securities Asset Management
Manchester,
Missouri
| $162K | +$44.5K | +63,800 | +38% |
|
|
OCG
3
Opus Capital Group
Cincinnati,
Ohio
| $32K | – | – | – |
|
|
AIP
4
Almanack Investment Partners
Wayne,
Pennsylvania
| $29K | +$13.5K | +19,500 | +87% |
|
|
WJWM
5
Williams Jones Wealth Management
New York
| $27K | – | – | – |
|
|
GWI
6
Grace & White Inc
Ny,
New York
| $18K | – | – | – |
|
|
LDB
7
Lee, Danner & Bass
Nashville,
Tennessee
| $14K | – | – | – |
|
|
AA
8
AlphaMark Advisors
Ft. Wright,
Kentucky
| $10K | – | – | – |
|
|
GG
9
Gofen & Glossberg
Chicago,
Illinois
| $9K | – | – | – |
|
|
ECM
10
Estabrook Capital Management
New York
| $7K | +$7K | +10,000 | New |
|
11
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $4K | – | – | – |
|
|
CSWM
12
Cassady Schiller Wealth Management
Cincinnati,
Ohio
| $1K | +$1K | +1,750 | New |
|
NWBO Hedge Fund Activity: Q4 2021 in Review
13 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2021, worth a combined $576K — up 27% from $453K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NWBO positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Ancora Advisors, adding an estimated $262K.
- 13 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2021, up from 10 in Q3 2021.
- Funds reported $576K of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2021, up 27% quarter-over-quarter.
- 3 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2021 and 0 closed out, a net change of +3 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2021 was Ancora Advisors, an estimated $262K added.
Based on aggregated 13F filings for Q4 2021.